NASDAQ
2.19USD
+0.11 (+5.29%)
We have scored 4 news catalysts on Sera Prognostics, Inc. (SERA) over the past 12 months. The biggest single-day move next to one of them came Feb 24, 2026, when SERA closed −8.2%: “Enhabit (EHAB) Surges 22.6%: Is This an Indication of Further Gains?”. Coverage across the window leans positive (average ticker sentiment +0.35). Most of the impact sits in price momentum and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
84.3M
P/E
—
EPS
—
Beta
1.14
52W range
1.56-3.85
Day range
2.04–2.22
Open
2.09
Prev close
2.08
Volume
218.7K
Avg volume
26.9K
Dividend
0.00
IPO
2021-07-15
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Sera Prognostics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SERA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
